Full Text View
Tabular View
No Study Results Posted
Related Studies
Levosimendan Versus Dobutamine in Shock Patients
This study is currently recruiting participants.
Study NCT00093301   Information provided by Wentworth Area Health Services
First Received: October 5, 2004   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiogenic Shock
Septic Shock
Additional conditions recognized in this trial
Shock
Shock, Cardiogenic
Shock, Septic
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Infection
Inflammation
Myocardial Infarction
Myocardial Ischemia
Pathologic Processes
Sepsis
Systemic Inflammatory Response Syndrome
Vascular Diseases
Interventions listed in this trial
Levosimendan
Dobutamine
Additional drug interventions recognized in this trial
Simendan
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-Agonists
Anti-Arrhythmia Agents
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Protective Agents
Sympathomimetics
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Wentworth Area Health Services
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services